Weekly reports come to my desk informing me of the activity in the Learning Management System (LMS) and what specific eLearning modules have been completed and by whom. To date, the HLA Reporting module has had the highest number of participants, while the Lymphoma (Forms 2018/2118) and Plasma Cell Disorders (2016/2116) eLearning modules have had the lowest. 
We have distanced learners with a wide range of experiences who have asked for more training. While utilizing eLearning modules will help ensure consistency in data reporting and improved accuracy of the data, our ultimate goal is to use the LMS as a way to credential data managers. 
Standardizing a training program will validate the knowledge, education, and expertise that is required to be a professional HCT data manager for CIBMTR. A certifying program will help promote recognition in the research community and give validity to the role that a Data Manager plays in transplant success. 
These are busy times, and work never ends, but I encourage your participation in the LMS which will set the foundation for building and improving our training offerings and their rippling benefits. 
Lori Colt
Training and Development Specialist  
Quick Links



How to Set up an LMS Account


LMS Access Help Desk 

800-526-7809 x 8123


After entering the Learning Management System (LMS), locate the CIBMTR Data Manager eLearning modules. Use the 'Learn' dropdown in the top teal ribbon to select 'Catalog' - then 'CIBMTR'.


If you have any questions, please email:


Communicating Data Management Manual Changes

CIBMTR has recently released 24 Data Management Manuals to correspond with forms revision (phase 1). These documents are helpful resources when completing CIBMTR TED and comprehensive report forms. In addition to question-specific references, reviewing these manuals at regular intervals will refresh your knowledge of specific questions and reporting situations. CIBMTR views these resources as "living documents," subject to change as new information or clarifications need to be shared. As such, data managers are encouraged to use the electronic version of the manual sections available at CIBMTR's Data Management Manual website to ensure that the latest version is viewed.


A version number and date have been added to the footer of the new manual releases to track changes to the manuals. As changes are made to the manual between major form revisions, the version number will increase. For example, the manual section for the Pre-TED (Form 2400) was released in October 2013; if a change was made to the manual, the version number would increase from version 3.0 (current) to version 3.1.


Updates to the manuals that occur between major revisions will also be communicated to centers using the following methods:


Type of Change

Communication Method

Grammar, spelling, formatting, or minor changes that do not affect reporting.


Changes tracked in the update log - "Manual Change History", located at end of manual section.

Changes that clarify reporting, but do not change the intent or meaning of the question or explanatory text.


Changes tracked in update log and in monthly CIBMTR Data Matters Training Newsletter.

Major changes, including those operational in nature, that alter the intent or meaning of the question or explanatory text.


Changes tracked in update log and in monthly CIBMTR Data Managers Training Newsletter. Timely E-blast generated to alert data managers of change.



Manual Change History





Version Number
Date of Change
Type of Change (Add/Remove/Modify)
Description of Change




Added "HLA Identical Siblings" to the following text in the introductory paragraph:


A separate Form 2005 should be completed for each recipient, cord blood unit, or non-NMDP donor; however, only the recipient form is required for syngeneic transplants and HLA identical siblings.




Added "(Revision 5)" to title of document




Tandem IT Forum - please invite IT partners to attend

CIBMTR - IT and NDMP Bioinformatics will be hosting an IT Forum Wednesday, February 26th, 2014 during this year's BMT Tandem Meetings. We're targeting a group ready to discuss methods to improve electronic data submission and retrieval - we would like your input! The Agenda will include discussion on CIBMTR systems and IT strategies, the AGNIS Application, the Data Back to Center tool, updates on the CIBMTR Data Warehouse strategy, as well as a presentation by Director of NMDP Bioinformatics Research, Martin Maiers.


We are proposing a project to use the BRIDG model, as discussed in the EMR users group, to facilitate collection of data that is also needed for the SCTOD database. If you are interested in reviewing more information on the BRIDG model in advance of the meeting, please refer to


The types of individuals we think would be interested in the above session would include: Enterprise Architects, Data Architects, Data Modelers, or anyone else who is involved with the electronic storage of BMT data at your institution.


To register for the IT Forum, please visit the BMT Tandem Meeting web site. Here is a link to the agenda:


Any questions can be addressed to





When reporting the 'best response to line of therapy' (Question 229 on Form 2016 PCD) - what criteria documents progressive disease (PD) in myeloma patients?



Documenting progressive disease requires one or more of the following criteria:

  • Increase of >25% from the lowest response value achieved in the serum M-component with an absolute increase of >0.5 g/dL (serum M-component increases of >1 g/dL are sufficient if the starting M-component is >5 g/dL); and/or
  • Increase of >25% from the lowest response value achieved in the urine M-component with an absolute increase of >200 mg/24 hours; and/or
  • For recipients without measurable serum and urine M-protein levels, the difference between the involved and uninvolved free light chain levels with an absolute increase >10 mg/dL; and/or
  • Bone marrow plasma cell percentage with an absolute percentage >10%; and/or
  • Definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; and/or

If progression is based on one of the biochemical markers (serum and/or urine monoclonal protein by electrophoresis or immunofixation), a second assessment is required to confirm the progression.  All other studies or findings do not require a confirmation.

Send your questions into The answer may be in a future newsletter.
CIBMTR Training  
Thank you to the contributors for this month's newsletter: 
Matt Petcoff, Senior CRA; Bridget Wakaruk, CIT Project Coordinator; Tamara Leziak, CRC